GLAND(Gland Pharma Limited)
30.11.2022 - CITI on Gland Maintain Sell CMP 1819.95 Target 1920
30.11.2022 - MS on Gland Maintain Overweight CMP 1819.95 Target 2558
30.11.2022 - GS on Gland Maintain Buy CMP 1819.95 Target 2530
27.10.2022 - CITI on Gland Maintain Sell CMP 1898 Target 1920
18.10.2022 - MS on Gland Maintain Overweight CMP 2156.05 Target 2748
23.08.2022 - GS on Gland Maintain Buy CMP 2350 Target 2830
19.08.2022 - BOFA on Gland Maintain Buy CMP 2415.5 Target 3200
21.07.2022 - CITI on Gland Maintain Sell CMP 2329.05 Target 2140
21.07.2022 - Jefferies on Gland Maintain Buy CMP 2329.05 Target 2916
21.06.2022 - CLSA on Gland Maintain Buy CMP 2568 Target 3450
23.03.2022 - Jefferies on Gland Pharma Maintain Buy CMP 3200 Target 4578
24.01.2022 - Jefferies on Gland Pharma Maintain Buy CMP 3568 Target 4578
24.01.2022 - Nomura on Gland Pharma Maintain Neutral CMP 3568 Target 3809
05.01.2022 - Jefferies on Gland Pharma Maintain Buy Target 4566
GLAND PHARMA Q4FY21 : 18.05.2021
* Net Profit Rs 260 cr (Up 37% YoY)
* Ebitda At Rs 375 cr (Up 31%) ; Ebitda Margin At 40% vs 42%
* R&D Expenditure Was Higher 32% YoY And Stood At 3.9% Of Sales
* Rest Of World Grew 129 % YoY As Company Entered New Markets
* COVID Led Demand Supported Growth And Entry Into Various Markets
* Filed 24 ANDA In FY21 And Received Approval For 32 ANDAS
* Launched 10 SKUs (6 Molecules) In Indian Markets